Love Pharma Inc (TSE:JOLT) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jolt Health Inc. has announced the acquisition of intellectual property for developing a transdermal patch technology for hydroxychloroquine (HCQ), aimed at improving treatments for malaria, lupus, and rheumatoid arthritis. The innovative delivery method is expected to mitigate side effects associated with oral HCQ and tap into a market projected to be worth $6 billion by 2027. This strategic move could revolutionize patient care in these underserved areas by utilizing a transdermal system that ensures safe and consistent drug dosage.
For further insights into TSE:JOLT stock, check out TipRanks’ Stock Analysis page.